Physician profile
Steven S Schiebert
NPI 1205042546
$77,540.59
in general payments reported to CMS, 2019-2025
8 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $525 · 2021: $3,858 · 2022: $9,661 · 2023: $15K · 2024: $21K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $63K · Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $62,755.07 |
| Food and Beverage | $550.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Choice Spine, LLC | $76,788.55 | 2019-2025 | Blackhawk Cervical Spacer System, Stratofuse, Boomerang |
| Spineart USA INC | $399.60 | 2020-2025 | Perla Tl |
| Centinel Spine, LLC | $87.27 | 2023 | Prodisc C Vivo |
| Baxter Healthcare | $75.48 | 2019-2025 | Floseal |
| Spine Wave, INC. | $75.00 | 2023 | Spinal Implant |
| Biohaven Pharmaceuticals, INC. | $69.68 | 2021 | |
| Ebi, LLC | $29.81 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Nuvasive, INC. | $15.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schiebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.